GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProText Mobility Inc (OTCPK:TXTM) » Definitions » Debt-to-EBITDA

ProText Mobility (ProText Mobility) Debt-to-EBITDA : 29.58 (As of Sep. 2014)


View and export this data going back to 2003. Start your Free Trial

What is ProText Mobility Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

ProText Mobility's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2014 was $1.42 Mil. ProText Mobility's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2014 was $0.00 Mil. ProText Mobility's annualized EBITDA for the quarter that ended in Sep. 2014 was $0.05 Mil. ProText Mobility's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2014 was 29.58.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for ProText Mobility's Debt-to-EBITDA or its related term are showing as below:

TXTM's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.31
* Ranked among companies with meaningful Debt-to-EBITDA only.

ProText Mobility Debt-to-EBITDA Historical Data

The historical data trend for ProText Mobility's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProText Mobility Debt-to-EBITDA Chart

ProText Mobility Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.59 -0.28 -0.30 -1.11 -1.61

ProText Mobility Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.19 -2.84 -1.57 -0.94 29.58

Competitive Comparison of ProText Mobility's Debt-to-EBITDA

For the Biotechnology subindustry, ProText Mobility's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProText Mobility's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProText Mobility's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ProText Mobility's Debt-to-EBITDA falls into.



ProText Mobility Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ProText Mobility's Debt-to-EBITDA for the fiscal year that ended in Dec. 2013 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.429 + 0.004) / -0.893
=-1.60

ProText Mobility's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2014 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.42 + 0) / 0.048
=29.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2014) EBITDA data.


ProText Mobility  (OTCPK:TXTM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


ProText Mobility Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ProText Mobility's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ProText Mobility (ProText Mobility) Business Description

Traded in Other Exchanges
N/A
Address
One West Las Olas Boulevard, Suite 500, Fort Lauderdale, FL, USA, 33301
ProText Mobility Inc is a Biotech Company developing a Hemp/CBD - Cannabis medicines platform for the legal cannabis industry, using proprietary live plant extraction processes & technologies. Protext has engaged in the research, testing, and development of bioavailable botanical products all-natural ingredients formulated for nutraceuticals and pharmaceutical applications through proprietary live plant extraction technology.
Executives
Peter Sealey director 37400 CENTRAL COURT, NEWARK CA 94560

ProText Mobility (ProText Mobility) Headlines

From GuruFocus